Todd Gluth

Cooley advised Drata, a trust management platform, on its definitive agreement to acquire SafeBase, a trust center platform designed for friction-free security reviews.

Cooley advised NETSTREIT on $275 million in additional financing commitments and amendments to its existing credit facilities agented by PNC Bank, National Association; Wells Fargo Bank, National Association; and Truist Bank. NETSTREIT is a Dallas-based real estate investment trust that acquires single-tenant net lease retail properties across the US. Partner Addison Pierce led the Cooley team advising NETSTREIT, which included partners Christina Roupas and Todd Gluth and associates Margaret Barreto and Cam Irwin.

Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised clinical-stage biopharmaceutical company Kura Oncology (Nasdaq: KURA) on its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of acute myeloid leukemia and other hematologic malignancies.